Member Info for AquaeSulis01

WIILG the skinbiotix platform can be used to produce a lysate from any bacteria strain so as different bacteria strains and the content of their lysed cells will have different properties then yes it could be used to produce other active ingredients in the cosmetic pillar for which SBTX would still receive a royalty payment

Shychap, you are in danger of going down a bit of a rabbit hole. The lysate is produced from lactobacillus rhamnosus, a gut-friendly bacteria.

https://www.healthline.com/nutrition/lactobacillus-rhamnosus

Also. if you listen to the response to Q2 at the last Investor Meets "Following the EU directive on retinol reduction do you know approximately what percentage of clients may be forced to reformulate products?" SA responds "..there is a directive on retinol reduction and going towards more greener products, we are the solution and we are the only solution right now"

Well with the Opti holdings value of PBX following their update and SBTX as the Croda launch now worth circa £10M this leaves the company valued at just £7.63M at today's sp so any indication that Dr Morepen revenues are pushing Opti towards profitability should see a considerable re-rate; believe we are due an update on the Dr Morepen launch shortly

Whilst it "doesn't impact year end figures" it is the loss of the anticipated mass production via the Bosch partnership that is behind the sp fall

"This announcement marks a major milestone in the close relationship between Ceres and Bosch and follows a successful prototype phase. Bosch is now preparing to start volume production of fuel cell systems incorporating Ceres' proprietary SteelCell® SOFC technology in 2024, aiming to achieve an initial annual production of around 200MW from manufacturing facilities in Bamberg, Wernau and Homburg and engineering locations in Stuttgart-Feuerbach and Renningen. The value to Ceres from 2021 to 2023 is around £23m, of which c.£6m is conditional on meeting certain KPIs based on performance.

Bosch, which owns 17.6% of the equity of the Company, and Ceres have been successfully working closely together since 2018 on the development and manufacturing of prototype fuel cell stacks. This announcement now marks the move towards mass production capability, enabled by Bosch's industrial expertise, and is an important step in helping to deliver Germany's green future. Acknowledging the role of fuel cells on the path to becoming carbon-neutral by 2050, Germany has recently announced €9 billion of government support for hydrogen and other clean energy technologies to help make the transition to de-carbonise society.

Ceres anticipates that initial production will satisfy demand for Bosch fuel cell systems, but in time could expand to meet the growing global demand for SteelCell® based stacks in multiple third party systems. Bosch's investment in Germany and its global footprint alongside Ceres' recently announced partnership with Doosan in South Korea now shows significant scale for planned production capacity for the SteelCell® technology worldwide. This announcement provides further validation of the Ceres licensing business model, as Bosch plans to scale from pilot production to mass manufacturing."

" A further ten metric tonnes of SlimBiome, approximating to £300k was taken from stock held by distributors for our two largest partners, and not included in these accounts. Once this stock overhang is clear this should have a material impact on reportable revenue."

https://www.lse.co.uk/rns/OPTI/final-results-3i1g5w7bid46kcw.html

That's where I am getting my facts from, where are you getting yours?

10 tonnes at £30k per tonne = £300K if forecast hit. Interesting difference between Daily Nouri feel Full taken once per day in 8 fl oz of added water (236ml) as opposed to Slimbiome Medical 100ml added water three times per day, feel Full certainly sounds more practical and affordable if it works

https://dailynouri.com/products/feel-full-prebiotic-lemonade?srsltid=AfmBOor_W2epdLnPLDKjVIBbB3cov0s8bJtuYGVAcdjoe1-qrFLF3uMz

https://optibiotix.online/pages/slimbiome-medical-faq?srsltid=AfmBOoplAUDz-S7j3e8rwdbc7K54cV7az2yPs4RxPpU-s6EVr3k_U9xG

Https://www.amazon.in/s?k=lightlife&ref=nb_sb_noss

Better than the disappointing Amazon India Dr Morepen sales 50+ bought last month for two of their lightlife products

PG nothing will appear until the patents are published and the risk of Competitors issuing spoiling patents has therefore elapsed. this should happen by mid march and following that expect the marketing publicity to occur in earnest. I will post on here the moment I see a related Croda patent published and the nature of any claims associated with it so in the meantime chill and get ready to jump in if the claims warrant it before the herd arrives!

Pretty decent set of results. Also from the full transcript this looks like a win win

"During the year, we made an all-share offer to acquire Tritax Eurobox plc, an externally managed REIT with

a portfolio of high-quality big box warehouses in Continental Europe, whose shares have consistently traded

at a significant discount to its net asset value. Although we were unsuccessful in buying the company due

to a rival, higher, offer, we instead negotiated a transaction with the eventual purchaser on behalf of our

joint venture, SELP, for six assets in Germany and the Netherlands, exchanging contracts in January 2025

and expect to complete on this transaction later in the first quarter. This is the part of the portfolio over which

we had the most conviction and our decision not to counterbid reflects our determination to maintain capital

discipline. "

To be honest I am more focused on the publication of the patent(s) and what they say because post their publication the launch material will start to appear and that will generate more interest than any RNS that confirms unspecified revenue received. According to the US Patent Publication process, it takes 14 weeks on average from date of filing (assuming any Croda patent is hitched to the already published SBTX Patents). The Project Timeline slide showed that patent filing was scheduled by End Nov 24 at the latest so Thursday March 6th 2025 could be a red letter day

https://www.uspto.gov/web/offices/pac/mpep/s1120.html#:~:text=The%20projected%20publication%20date%20normally,process%20takes%20about%20fourteen%20weeks.

Shychap " shareholders will only see the impact of these upon the Group's financial results at interims and full year" so if revenues received as verbally told by SA by Dec 24 they will appear in the Interims for H1 2025 next month so not long to wait, but I will also check the DFS Interims as well in case Toyin is right :)

Netcurtains, I am talking about SBTX Interims, there is unlikely to be anything specific in the Croda RNS unless the patents are published before then

I thought it already had been RNS'd. From the Dec 24 FY Results "Current trading and outlook

The profile of the Group has changed completely this year, and next year's FY25 results will better reflect this with bolstered sales from the in-house strategic pillars with revenues from AxisBiotix-PS sales and the introduction of Croda royalties, and also 12 months of Dermatonics' and nine months of Bio-Tech Solutions' contributions.

Now that commercialisation by Croda of SkinBiotix has begun, revenues are expected to start gradually. Croda is currently estimating future sales, but due to the highly confidential nature of its business and market, shareholders will only see the impact of these upon the Group's financial results at interims and full year, however, the Directors believe the potential enhanced commercial opportunities could be considerable."

Now as I have stated before, unlike some others, I do not expect pre-launch revenue to be material hence personally not expecting a further RNS in advance of the Interims out next month

Toyin, if revenues have been received in H1 then they will have to be reflected somewhere in the accounts , after all you can't just hide it under the sofa

Shy, We received verbal confirmation during the Dec Investor Meets that Croda revenues had been received Calendar Year 2024 so should be included in the Interims next month.

Elric, I dispute the wording that the Sederma process "usually" takes 7 years when the evidence suggests the process can take a minimum of 2 years and I would suggest a maximum of 7 years in a worse case scenario. A repeatable process is made up of a set number of measurable steps, and in the case of the matrixyl launch this included a full 6 month clinical trial step. Hence, the 5 years it will have taken to launch skinbiotix will no doubt have resulted from unexpected results along the way that led to some steps having to be repeated. Don't forget, SA first informed us to expect initial royalties within 2 years of launch, the best case scenario, however, we have subsequently been informed there were issues with the bacterial strain and then the additional properties found would both have led to steps having to be repeated and hence the delay.

Bel, of course Croda had to validate the claims, this they had achieved 31/07/2020 "Sederma has successfully replicated the lysate manufacturing process and achieved the same performance from the SkinBiotix® technology as established by the Company"

By 30/11/2021 Croda had scaled up and identified additional claims "Potential additional cosmetic claims for SkinBiotix® being investigated. Initial royalty revenues anticipated as planned in calendar year 2022"

Regarding the 7 years it takes to bring a product to market it is worth listening to karl Lintner who was responsible for bringing Matrixyl to market which was achieved in 2 years flash to bang "circa 1.54 in"

https://www.cossma.com/marketing/article/karl-lintner-the-history-of-matrixyl-peptides-are-here-to-stay-33234.html

So sbtx have on the face of it been played like a fiddle so little wonder SA went down the acquisition route to focus a few minds

Back on point, it seems that Umesh Modi are finally getting their act together with their advertising of over-the-counter pheet heel balm. This influencer has 165k subscribers and the video has received over 20k views so far

https://www.youtube.com/watch?v=A_Hm_1yUDQ0

If you listen carefully to the update it doesn't say sales of Dr Morepen have disappointed, in fact he states they have had "good success" from a product only launched in December and expect even better in the Summer when people exercise more. Besides, I thought the focus of the marketing was on resolving the health issues associated with Obesity such as diabetes, rife in, India rather than creating beach bodies.

"Speaking at the launch, Mr. Varun Suri, Managing Director of Dr. Morepen, said:

"India’s obesity market is expected to grow to $52.3 billion by 2032, reflecting the urgency to address

weight management with solutions that are both safe and effective. At Dr. Morepen, we believe in

science and trust, not shortcuts. I am thrilled to bring LightLife to India, where high-fat and high-carb

diets have contributed to a surge in obesity and diabetes. With LightLife, we address these challenges

without crash diets or harmful fads, offering freedom from complicated regimens. This program is not

just about weight loss—it’s about promoting a healthy, balanced lifestyle through globally respected

innovations like Slimbiome® and Intelicaps, empowering individuals with a scientifically validated,

trustworthy solution they can rely on."

https://www.morepen.com/public/uploads/media/Morepen67597dea6bfdb.pdf

Pressure on the competition regulator to encourage economic growth is raising expectations in the City that it will take weaker action following its investigation into the veterinary services market.

https://www.thetimes.com/business-money/companies/article/push-for-growth-could-tame-cmas-inquiry-into-vets-market-gpkn88l75